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ABSTRACT
The design of probes for the selective recognition of biopolymers (nucleic acids
and proteins) is a fundamental task for studying, diagnosing, and treating diseases.
Traditional methods utilize a single component (small molecule or oligonucleotide) that
binds directly to the target biopolymer. However, many biopolymers are unable to be
targeted with this approach. The overarching goal of this dissertation is to explore a
new, binary approach for designing probes. The binary approach requires two
components that cooperatively bind to the target, triggering a recognition event. The
requisite binding of two-components allows the probes to have excellent selectivity and
modularity.
The binary approach was applied to design a new sensor, called operating
cooperatively (OC) sensor, for recognition of nucleic acids, including selectively
differentiating between single nucleotide polymorphisms (SNPs). An OC sensor
contains two oligonucleotide probe strands, called O and C, each with two domains.
The first domain contains a target recognition sequence, whereas the second domain is
complementary to a molecular beacon (MB) probe. Binding of both probe strands to the
fully matched analyte generates a full MB probe recognition site, allowing a MB to bind
and report the presence of the target analyte. Importantly, we show that the OC sensor
selectively discriminates between single nucleotide polymorphisms (SNPs) in DNA and
RNA targets at room temperature, including those with stable secondary structures.
Furthermore, the combinatorial use of OC sensors to create a DNA logic gate capable
of analyzing DNA sequences of Mycobacterium tuberculosis is described.
iii

The binary approach was also applied to design covalent inhibitors for HIV-1
reverse transcriptase (RT). In this application, two separate pre-reactive groups were
attached to a natural RT ligand, deoxythymidine triphosphate (dTTP). Upon binding of
both dTTP analogs in the RT active site, the pre-reactive groups are brought into the
proper proximity and react with each other forming an intermediate that subsequently
reacts with an amino acid side chain from the RT. This leads to covalent modification of
RT, and inhibition of its DNA polymerase activity. This concept was tested in vitro using
dTTP analogs containing pre-reactive groups derived from β-lactamase inhibitors
clavulanic acid (CA) and sulbactam (SB). Importantly, our in vitro assays show that CA
based inhibitors are more potent than zidovudine (AZT), a representative of the
dominant class of RT inhibitors currently used in anti-HIV therapy. Furthermore,
molecular dynamics simulations predict that complexes of RT with these analogs are
stable, and point to possible reaction mechanisms. The inhibitors described in this work
may serve as the basis for the development of the first covalent inhibitors for RT.
Moreover, the pre-reactive groups used in this study can be used to design covalent
inhibitors for other targets by attaching them to different ligands. Overall, the work
presented herein establishes the binary approach as a straightforward way to develop
new probes to selectively recognize nucleic acids and proteins.
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CHAPTER 1: GENERAL INTRODUCTION
Proteins and nucleic acids are important biopolymers that perform a wide range
of biological functions. The development of probes for the recognition of these
biopolymers is a fundamental task for studying, diagnosing, and treating disease.
Indeed, substantial efforts have been made to create new probes for this purpose.
One of the most important characteristics of a probe is selectivity. Selectivity is the
ability of a probe to differentiate its target from non-target molecules, and thus is a
range from low (poor) to high (excellent). Traditional methods to develop probes have
focused on developing a single ligand designed to selectively recognize the target
(Figure 1). This recognition event may report the presence of the target or alter its
function. Traditionally, selectivity is achieved by fine-tuning the interaction between the
target and ligand. Adjusting chemical groups at different positions to promote high
affinity for the target, thus hopefully reducing the likelihood of the probe binding to
other biopolymers. Inherently, this limits the degree of selectivity achievable without
compromising other important characteristics of the probe. Additionally, the vast
majority of the human proteome has yet to be targeted with a probe for research or
treatment purposes, perhaps to due limitations of the traditional strategy. Furthermore,
a large portion of genomic diversity is due to single nucleotide polymorphism (SNPs),
and design of probes for recognition of SNPs is still difficult. Thus, new approaches to
design probes for recognition of both proteins and nucleic acids are needed.
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Nature’s Approach
There are many examples of natural biological systems with distinct and highly
selective one-to-one complexes between two partner molecules: antibody-antigen,
receptor-ligand, and kinase-substrate. Mimicking this approach to design probes for
recognition of nucleic acids and proteins has been successful. However, nature uses
more than just the one-to-one approach. Often, recognition events only occur when
multiple partners bind to each other. One of the classical examples is the excellent
selectivity of sequence specific endonucleases. Structural studies of the an
endonuclease from Escherichia coli (E. coli), EcoRV, revealed an interesting
conformational change when EcoRV is bound to its target DNA [1]. EcoRV changes
conformations creating a new binding site for the divalent magnesium ions required for
cleavage of the target DNA. This conformational change only occurs when EcoRV
binds to its target-DNA, allowing this enzyme to perform its function with high
selectivity. This classical example illustrates how natural biological systems have
evolved to require multiple binding events prior to a recognition event. Inspired by this,
we propose a binary approach to design selective probes for recognition of detection
of nucleic acids and proteins.
The Binary Approach
This work explores the hypothesis that a binary approach, using two molecules
that must simultaneously bind a target biopolymer, will improve selectivity over singlecomponent systems (Figure 1). The general binary scheme requires a target with two
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ligand-binding sites adjacent to each other (Figure 2). Two analogs of these ligands
are synthesized, each containing an additional function group. When both ligand
analogs bind to the target, the additional functional groups are brought in proximity
creating a recognition event. This event depends on the functional groups used, but
can be generation of a detectable signal or generation of a new group that can alter
the activity of the target. In any case, this recognition event only occurs when both
ligands correctly bind to the target, increasing the selectivity of the recognition event
since random interactions between the two groups in solution is unlikely to occur.
Furthermore, it is unlikely that the ligands selected would bind near each other on
another target.
It is important to note that all nucleic acids can fulfill the requirement of two
adjacent ligand-binding sites. Ligands can be designed to bind to the target at a
specific locus through Watson-Crick base pairing. For proteins, ligands that bind at
adjacent sites must be available, or efforts must be made to select a new ligand that
binds near a known ligand. Fortunately, many enzymes naturally facilitate the binding
of multiple small molecules or macromolecules to perform their function, and thus
these can be used as ligands to develop a probe following the binary approach.
Additionally, enzymes are an important drug class and research area. Indeed, up to
40% of small-molecule drugs target enzymes and an estimated 80% of potential drug
targets are enzymes [2,3]. Regardless if the target is protein or nucleic acid, the extra
functional group attached to the ligands can vary greatly in its composition. For
example, it may consist of an oligonucleotide, reactive small molecule, or a
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fluorescent small molecule. Herein, we explore the binary approach to design probes
for the selective recognition of nucleic acids and proteins.
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Figures and tables

Figure 1. Classical approach to design probes for recognition of nucleic acids
or proteins.
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Figure 2. Binary approach to design probes for recognition of nucleic acids or
proteins.
In a binary approach, two ligands (blue) are created with additional functional groups (half circles).
Upon binding of both ligand analogs to the target, the additional functional groups are facilitated near
each other allowing a recognition event to occur.
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CHAPTER 2: OPERATING COOPERATIVELY (OC) SENSOR FOR
HIGHLY SELECTIVE RECOGNITION OF NUCLEIC ACIDS†
Introduction
The analysis of single nucleotide variation in DNA and RNA is important for
genotyping of single nucleotide polymorphisms [4,5], somatic mutations [6-8], and
methylation changes associated with aging and cancer [9-11]. A molecular beacon
(MB) probe [12] is a hybridization sensor that has been extensively utilized for the
analysis of single nucleotide variation [13-19]. A traditional MB probe is a stem-loop
folded DNA oligonucleotide, with fluorophore and quencher dyes conjugated to
opposite ends (Figure 3A). MB probes have found multiple applications in the analysis
of biological molecules due to their ability to produce a fluorescent signal
instantaneously upon hybridization to complementary nucleic acids. MB probes were
found to be more specific towards single base substitutions than linear probes [20-24].
However, in many cases, accurate SNP genotyping still requires elevated temperature
and/or measuring melting temperature profiles. Moreover, the design of MB probes
remains challenging due to the problems of stem or loop invasion [16,25,26] and poor
hybridization with structured sequences [27-31]. Additionally, MB probes are
expensive commercial products. The use of a limited number of MB probes for the
†

Work in this chapter was previously published: Cornett EM, O'Steen MR, Kolpashchikov DM (2013)

Operating Cooperatively (OC) sensor for highly specific recognition of nucleic acids. PLoS ONE
8:e55919.
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analysis of numerous target sequences is an attractive perspective. In this approach,
one, or several, MB probes can be optimized to avoid stem and loop invasion and
used as universal sensors for any DNA or RNA analytes (so-called universal MB
probes [32]). This approach may enable multiplex genotyping of millions of SNPs in a
low budget format. Here we report the design of a sensor that uses a single MB probe
to detect multiple nucleic acid sequences.
The sensor has a straightforward design and demonstrates excellent SNP
selectivity at ambient temperatures. Additionally, this new sensor is suitable for the
analysis of nucleic acids folded in stable secondary structures, such as bacterial 16S
rRNA. We have been exploring strategies for indirect binding of an MB probe to
specific nucleic acids. The first strategy, binary DNA sensors (BDSs), used two DNA
adaptor strands (m and f in Figure 3B). The f and m strands hybridized to both an MB
probe and an analyte, forming a DNA four-way junction-like structure (Figure 3B). This
approach demonstrated unprecedented selectivity at room temperature [32-34]. The
BDS had a straightforward design and enabled detection of stem-loop folded
sequences [27,28,34]. The triethylene glycol linkers, situated between the MB-binding
and analyte binding arms (dashed lines in Figure 3B) were necessary to promote the
stabilization of the DNA four-way junction conformation that produces high
fluorescence [32,33]. However, these linkers increased the cost of an adaptor strand
by a factor of 5. In an effort to avoid the non-nucleotide modification we explored
alternative approaches, which resulted in the design of a double-crossover (DX) tile
sensor (Figure 3C) [35,36]. The construct takes advantage of the DX tile, a DNA
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structure first investigated by Fu and Seeman [37]. The DX tile sensor consisted of an
MB probe, three unmodified DNA adaptor strands (a, b, and c), and an analyte, which
together formed a penta-partite complex (Figure 3C). However, the sensor had only
moderate selectivity towards a single nucleotide substitution due to the required
formation of at least 26 base pairs between the analyte and the adaptor strands.
Indeed, long stable hybrids between a probe and a nucleic acid analytes are known to
reduce probe selectivity [38]. In an effort to design a nucleic acid sensor that is not
cost-prohibitive, yet still maintains excellent SNP selectivity, we report here a new
SNP-selective sensor, named ‘operating cooperatively’ or OC sensor (Figure 3D) [39].
In this study, we demonstrate the exceptional SNP selectivity of the OC sensor at
room temperature, determine the limit of detection (LOD), and demonstrate how this
sensor can be tailored to analyze stem-loop folded DNA and bacterial 16S rRNA.
Materials and Methods
Reagents
All oligonucleotides (sequences listed in Table 1) were custom-made by
Integrated DNA Technologies, Inc (Coralville, IA). T7 RNA polymerase, PstI, and
NTPs were purchased from New England Biolabs (Ipswich, MA). Chemicals were
purchased from Sigma-Aldrich (St. Louis, MO). pEC16SM plasmid was a generous gift
from Dr. Dedkova (ASU).
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Fluorescence Assay
For the fluorescence assays, UMB1 was added to a buffer containing 50 mM
MgCl2, 50 mM Tris-HCl, pH 7.4, at a final concentration of 50 nM. O and C strands,
and either matched (rs87T, E.coli f1, rs14G) or mismatched (rs87C, B.sub f1, rs14A)
strands were added to a final concentration of 200 nM, and 500 nM, respectively. Final
sample volumes were 120 mL for DNA analytes and 60 mL for bacterial 16S rRNA
analytes. For assays with DNA analytes, samples were incubated for 15 minutes at
room temperature (22C). For fluorescence assays with RNA analytes, samples were
incubated for 5 minutes in 90°C water bath, followed by 15 minute incubation at room
temperature prior to recording fluorescence spectra. Fluorescence spectra were
recorded on a Perkin-Elmer (San Jose, CA) LS-55 Luminescence Spectrometer with a
Hamamatsu xenon lamp (excitation at 485 nm; emission 517 nm). All experiments
were repeated at least three times, and data is shown as the mean with error bars
representing one standard deviation from the mean.

Preparation of Bacterial 16S rRNA Analytes
Total RNA was isolated from E. coli (ATCC 8739) and B. subtilis (ATCC 9372)
using Omega Biotek Bacterial RNA isolation kit following the manufacture’s
recommended protocol. Isolated RNA yield was determined, and the presence of 16S
rRNA was seen using agarose gel electrophoresis (Figure 5). E. coli 16S rRNA
transcript was obtained using in vitro transcription with pEC16SM plasmid, which
contains the 16S rRNA gene from E. coli strain A19. PstI was used to linearize
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pEC16SM. The in vitro transcription reaction mixture (300 mL) contained linearized
pEC16SM (1 mg), NTPs (4 mM each), T7 RNA polymerase in NEB RNA pol reaction
buffer supplemented with MgCl2 (20 mM) and bovine serum albumin (25 mg/mL). The
reaction was incubated at 37uC for 2 hours. The transcript was collected by ethanol
precipitation. The concentration of rRNA transcript was determined by comparison of
gel band intensity with gel purified transcript (Figure 4).
Results
The OC sensor uses two unmodified DNA adaptor strands (O and C), each of
which binds to a MB probe and a analyte (Figure 3D). The design of the sensor was
adjusted to room temperature (22°C). For these conditions, strand O had two 5 or 6
nucleotide MB-binding arms. Thus, the two short binding arms had a very weak
interaction with MB probe in the absence of analyte, thus ensuring low fluorescent
background. Strand C had 8 or 9 nucleotide MB binding arms; this length was required
for the formation of stable DNA four-way junction associates [37]. The analyte binding
arm of strand C can be adjusted to provide high mismatch selectivity or stabilization of
the OC complex as demonstrated below. Figure 6A shows a design of the OC sensor
for the recognition of a human genomic DNA sequence that is known to have a SNP
(rs876724). This analyte contains a mutation which has been suggested as a useful
marker for human identification in forensic applications [40]. The sensor fluoresced
only in the presence of the matched rs87T sequence, but not in the presence of an
alternative allele (Figure 6B). The limit of detection (LOD) of the sensor was found to
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be 5.5 nM (Figure 7 blue line), which is somewhat above the detection limit of a typical
MB probe [12-16,32]. Importantly, the presence of high excess (500 nM) of a singlebased substituted analyte did not jeopardize the assay: the cognate analyte was
detected with the LOD of 12 nM (Figure 7 red line). Importantly, the LOD is well below
the concentration achievable by PCR (~100 nM). In order to demonstrate general
applicability of the approach, an OC sensor was designed to recognize an alternative
human SNP (rs1490413 Figure 8). Again, the sensor demonstrated excellent SNP
discrimination at room temperature. The design of the new sensor was
straightforward: (i) the sensor utilized the same MB probe; (ii) only the analyte binding
arms of the sensor were changed to complement to the new target.
Natural single stranded nucleic acids are often folded in stable secondary
structures. Stable structures prevent hybridization probes, including the MB probe,
from interacting with such analytes [27-30,41]. A common approach to overcome this
difficulty is to target only unstructured fragments of natural RNAs. This limits the
choice of hybridization probes and often prevents analysis of SNPs located in stem
regions of such analytes. Here we demonstrate that the OC sensor is capable of
analyzing folded nucleic acids. As a model, a fragment of E. coli 16S rRNA (E. coli f-1
in Figure 9A) was used as a specific analyte and a corresponding fragment of B.
subtilis 16S rRNA (B. sub f-1 in Figure 9A) was used as a non-specific analyte. These
analytes were DNA olignonucleotide mimics of the actual RNA sequence. Analysis of
16S rRNA is important for classification of bacteria species and for molecular
diagnostics of infectious diseases [42-45]. On the other hand, 16S rRNAs, as well as
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their DNA amplicons, can fail to hybridize to oligonucleotide probes [46,47]. In this
study, we have randomly selected a fragment of E. coli 16S rRNA folded in a typical
stemloop structure with a bulge in the middle of the stem (Figure 9A). The predicted
melting temperature of this stem was 84.5°C according to IDT Oligo Analyzer software
(experimental conditions set at 50 mM MgCl2, 50 mM monocharged ion).
The OC sensor for selective recognition of the stem-loop folded E. coli f-1 took
advantage of a C2 strand equipped with a long analyte binding arm, containing 30
nucleotides (Figure 9B). The long arm allows the C2 strand to tightly hybridize to an
extended portion of the analyte and unwind its secondary structure. However, the long
arm may also allow a stable complex to form between C2 and B.sub f-1 analyte. Thus,
the O2 strand is designed to contain an analyte binding arm of only 12 nucleotides
and will hybridize tightly only to the fully complementary E.coli f1. Indeed, high
fluorescence was registered only in the presence of a fully matched strand, but not in
the presence of a mismatched B.sub f-1 (Figure 9C).
In order to test the OC sensor against actual bacterial 16S rRNA samples, we
used in vitro transcription to obtain E. coli 16S rRNA. The OC sensor was able to
recognize and give high fluorescent signal in the presence of the 16S rRNA transcript
(Figure 10A). However, an additional annealing step was required, likely due to a very
stable structure of the long 16S rRNA compared to our mimic analytes. Additionally,
the OC sensor was applied to the identification of 16S rRNA collected from bacteria
samples. The total RNA from E. coli and B. subtilis was obtained and the OC sensor
correctly identified the E. coli 16S rRNA. The OC sensor produced a high fluorescence
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signal in the presence of E. coli RNA, but gave a low signal in the presence of B.
subtilis RNA or no analyte (Fig. 6B). Thus, the OC sensor is suitable for sequence
selective recognition of conformational constrained natural RNAs.
Discussion
MB probes have become an important tool of molecular diagnostics, especially
in real-time PCR (rtPCR) format [13,15]. However, the application of MB probes in
practice suffers from a number of problems including stem invasion and inability to
analyze folded RNA and DNA. Moreover, despite improved selectivity towards
mismatched analytes, MB probes still require monitoring of melting profiles for
accurate SNP genotyping [13-15]. Multicomponent sensors that use indirect binding of
an MB probe to a target DNA or RNA analyte offer a solution for these pitfalls. In this
approach, a limited number of optimized MB probes can provide a toolbox for the
analysis of millions of human and bacterial SNPs with no need to design a pair of
unique MB probes for each new SNP of interest.
Previously, our lab introduced two different designs for MB probe-based
multicomponent sensors, each with its respective disadvantages[33,35]. The OC
sensor reported here demonstrated marked improvement over the previous designs: it
is less expensive than binary DNA sensor and more selective towards SNPs than a
DX-tile sensor. Additionally, the OC sensor is suitable for the analysis of secondary
structure folded DNA and RNA. Herein, the utility of the OC sensor was demonstrated
by adapting an OC sensor for detection of bacterial 16S rRNA. Therefore, the
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approach described in this study has potential to become useful for instantaneous
detection of nucleic acids in homogeneous solutions. OC sensors used in this study
were designed to operate at room temperature to avoid any required temperature
control for the hybridization reaction between probes and analyte. However, the
design could likely be adjusted to function at elevated temperatures (50–60°C) for
applications such as quantitative real time PCR.
The OC sensor produces fluorescent signal instantaneously upon hybridization
to a specific nucleic analyte. The MB probe binds to the analyte indirectly, e.g. through
two unmodified DNA oligonucleotide adaptor strands. This gives an opportunity to
optimize a single MB probe for the analysis of multiple DNA or RNA sequences. The
approach provides a versatile tool for nucleic acid analysis at ambient temperature
that is SNP specific and capable of analyzing stem-loop folded nucleic acids. Thus the
OC sensor represents a promising tool for SNP analysis in homogeneous solution,
which might be used for detection and genotyping of bacteria or human SNPs.
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Figures and tables

Figure 3. Molecular beacon-based sensors for nucleic acid detection.
A)
B)
C)
D)

Conventional MB probe [12].
MB-based binary DNA sensor (BDS) [33]. Dashed lines indicate triethylene glycol linkers.
DX-tile based sensor [35].
OC sensor introduced in this study.
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Table 1. Sequences of oligonucleotides used in the OC sensor study.
Name

UMB1
rs14G
rs14A
E.coli f-1
B.sub f-1
rs87C
rs87T
O1
C1
O2
C2
O3
C3

Sequence

Purification

5'-/FAM/CGCGTTAACATACAATAGATCGCG/BHQ1/
5'-ACTGGGCTGATGTGGGTTCTTTGCAGAACTG
GCTGGCCTCAGAGCAGGGA
5'-ACTGGGCTGATGTGGGTTCTTTGCAAAACTG
GCTGGCCTCAGAGCAGGGACCGCGGCCAGTTCT
GCAAAGAACCCACCGCGG
5'-TAGTCCGGATTGGAGTCTGCAACTCGACTCC
ATGAAGTCGGAAT
5'-CAGTTCGGATCGCAGTCTGCAACTCGACTGC
GTGAAGCTGGAAT
5'-ATACCACTGCACTGAAGTATAAGTACATTTTTT
GTCACACTCTGCTAACT
5'-ATACCACTGCACTGAAGTATAAGTATATTTTTT
GTACACTCTGCTAACT
5'-TATTGTTATACTTCAGTGGCGATC
5'-AATATACTATGTTAACG
5'-TATTGTTCCAATCCGGACGCGATC
5'-ATTCCGACTTCATGGAGTCGAGTTGCAGACA
TGTTAACG
5'-TATTGTAAGAACCCACATGCGATC
5'-AGTTCTGCAATGTTAACG
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HPLC
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD
SD

Figure 4. E. coli 16S rRNA in vitro transcript concentration was determined
using agarose gel electrophoresis.
In vitro E. coli 16S rRNA transcript concentration determination by 1% agarose gel electrophoresis with
GELRED staining. Transcript was gel purified and concentration determined using a
spectrophotometer. Several concentrations of known gel purified transcript (lanes 1–4), as well as 1 µL
from two dilutions of unknown concentration used in the fluorescent assays. The 1/8 dilution sample
was determined to be equal in intensity to 166 ng band. This was used to determine the concentration
of all in vitro transcript samples used in fluorescent assays.
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Figure 5. Agarose analysis of total RNA isoltation from E. coli and B. subtilis.
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Figure 6. OC sensor selectively recognizes rs876724 SNP T allele.
A) Sensor in complex with rs87T analyte and UMB1 probe. The sensor was designed to recognize the
thymidine containing allele, while discriminating against the alternative cytosine containing allele.
MB-binding arms are shown in cyan.
B) Fluorescent response of OC sensor specific to rs87T allele sequence in the absence or presence of
specific or non-specific analytes.
C) Mean signal-to-noise ratios of four independent experiments with error bars indicating one standard
deviation.
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Figure 7. OC sensor limit of detection (LOD).
O1, C1, and UMB1 probe were used to analyze low concentrations of the matched analyte (rs87T). The
limit of detection (LOD) was calculated as the analyte concentration that triggered a fluorescent signal
equal to the average fluorescence of the background from three independent measurements plus three
standard deviations of the average back- ground fluorescence. Data shown were plotted as the mean
with error bars representing one standard deviation from the mean from three independent trials. LOD
was determined in the absence (blue line) or in the presence (red line) of 500 nM of mismatched
analyte (rs87C). The green dashed lines represent the respective thresholds and the black dashed lines
represent the respective LODs.
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Figure 8. Design and validation of an OC sensor to selectively recognize
rs1490413 SNP.
A) Signal-to-noise ratios for OC sensor designed to detect human genomic SNP rs1490413 allele G.
B) The OC sensor complex formed with UMB1 probe and rs14G analyte.
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Figure 9. Design and validation of an OC sensor for recognition of secondary
structure-forming fragment of E.coli 16S rRNA.
A) Sequences and the predicted secondary structure of stem-loop folded fragments of 16S rRNA. The
nucleotide variations in E. coli and B. subtilis 16S rRNA are shown in magenta.

B) OC sensor in complex with fully matched E.coli f-1 sequence. MB binding arms of strands O2 and
C2 are shown in cyan.

C) Signal-to-noise ratio of fluorescent response of OC sensor in the presence of absence of E.coli or
B. subtilis 16S rRNA mimics. The assay was conducted in 50 mM Tris HCl, pH 7.4, 50 mM MgCl 2 at
room temperature (22°C). The data represents the signal-to-noise ratios of three independent
experiments with error bars indicating one standard deviation from the mean.
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Figure 10. An OC sensor selectively recognizes bacterial 16S rRNA.
A) Fluorescent response of OC sensor in the present of various concentrations of E. coli 16S rRNA
generated by in vitro transcription in vitro transcript. Graph depicts the mean fluorescence of three
independent experiments. Error bars represent the standard deviation.
B) Fluorescent spectra of OC sensor in the presence of total RNA isolation from E. coli and B. subtilis
bacteria.
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CHAPTER 3: MOLECULAR LOGIC GATES FOR DNA ANALYSIS:
DETECTION OF RIFAMPIN RESISTANCE IN M. TUBERCULOSIS
DNA‡
Introduction
Molecular logic gates made of DNA have attracted significant attention because
of their biocompatibility, simple design, and ability to analyze and control biological
systems [48-54] To fuel further development of the field, applications of DNA-based
gates to solve significant biological problems are required. Recently, our lab
characterized a set of DNA logic gates (YES, NOT, AND, and OR) and demonstrated
their connectivity by designing ANDNOT and XOR operations [53,54]. The gates used
hybridization of DNA strands with a molecular beacon (MB) probe to produce a
fluorescent output. Herein, DNA logic gates are applied to solve an important
biomedical task: analysis of multiple DNA sequences containing a complex set of
mutations.
Mycobacterium tuberculosis (Mtb) infects approximately 2 billion people all over
the world and is responsible for about 2 million deaths each year [55]. Approximately
10% of all patients are infected by strains of Mtb that are drug-resistant; these strains
are primarily resistant to antibiotics rifampin (Rif) and isoniazid [55]. Currently, there is

‡

Work in this chapter was previously published: Cornett EM, Campbell EA, Gulenay G, et al. (2012)

Molecular logic gates for DNA analysis: detection of rifampin resistance in M. tuberculosis DNA. Angew
Chem Int Ed Engl 51:9075–9077.
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an urgent need for cost-effective diagnostic methods that can detect Mtb in clinical
samples and differentiate between drug-susceptible and drug resistant Mtb strains
[56-60]. Several assays exist to detect mutations responsible for antibiotic resistance
[56,58-62]. One of the most advanced commercial assays, Cepheid’s Expert MTB/RIF
[63-66], takes advantage of real-time PCR (rtPCR) and MB probes [13,67]. MB
probes,

first

introduced

by

Tyagi

and

Kramer

[12],

are

stem–loop-folded

oligonucleotides with fluorophore and quencher dyes attached at opposite ends
(Figure 11). Hybridization of an MB probe to a complementary DNA or RNA switches
the probe to an elongated form, thus separating the fluorophore from the quencher.
The resultant fluorescence increase can be quantitatively measured, which is the
basis for the widespread application of MB probes in real-time detection of nucleic
acids. In the Expert MTB/RIF assay, five MB probes were designed to span the highly
variable 81-nt core of the bacterial amplicon where approximately 96% of all Rifresistant mutations are located (Figure 11A). The probes were complementary to the
drug-susceptible wild-type (WT) sequence [68]. A signal from all five MB probes
indicated the presence of the WT (no mutation in the core region). Absence of a signal
from all five probes indicated that a sample was Mtb negative. Failure of at least one
MB probe to produce a signal indicated the presence of a Rif-resistant Mtb (Figure 1A,
right). Formal logic suggests that the Expert MTB/RIF process is redundant: it uses
five outputs to answer “yes” or “no” to the two following questions: 1) Is there Mtb DNA
present in a sample? 2) Does the Mtb DNA contain a mutation that confers rifampin
resistance? Additionally, five expensive, hard-to-optimize MB probes along with a five
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channel fluorescent reader are needed for the assay. Formally, the task can be
executed by using only two outputs. Herein we propose to use a DNA-based YES
logic gate to answer the first question and an OR logic gate to answer the second
question. Each gate uses a separate fluorescent output, thus the detection process
requires only two MB probes.
Materials and Methods
Materials
All of the oligonucleotides were custom-made by Integrated DNA Technologies,
Inc (Coralville, IA). Standard reagents for buffers were purchases from Fisher
Scientific. DNA grade water was used for preparation of al samples and buffers. The
sequences of all strands of the proposed oligonucleotide sensor as well as analytes
are given in Table 2.

Fluorescence Assay
For the fluorescence assay with both YES and OR logic functions combined, all
five M strands (50 nM), three F strands (200 nM), strands C, D (200 nM each), and E
(100 nM), UMB1 (25 nM), and UMB2 (25 nM) were mixed in a buffer containing 50
mM MgCl2, 50 mM Tris-HCl, pH 7.4, in the presence or absence of 250 nM wild-type
(WT) or mutant analyte (M1–M5). Final sample volumes were 120 mL. Fluorescence
spectra were recorded on a PerkinElmer (San Jose, CA) LS-55 luminescence
spectrometer with a Hamamatsu xenon lamp (excitation at 550 nm; emission at 580
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for UMB1 and excitation at 485 nm; emission 517 nm for UMB2) after 15 min
incubation at room temperature (22C). The data was analyzed using Microsoft Excel.
The means of three independent experiments were calculated and converted to
signal-to-background Figure 2. The background was considered the sample with all
oligonucleotides except analyte. All signals above a threshold set at S/B=1.5 were
considered true outputs for either the YES or the OR logic gates.
Results
Analyte WT represents wild-type Mtb sequence with no resistance-causing
mutations. All five mutant sequences (named here M1–M5; see Table 2) were from
the highly variable 81-nt core, each with a separate known mutation that confers Rif
resistance. They were previously used for characterization of Rif resistant Mtb strains
by conventional methods [61,62,68-71]. The YES logic gate consisted of the three
DNA stands (a, b, and c in Figure 11B) and a universal MB probe (UMB1). In the
presence of any Mtb DNA, either WT or Rif-resistant M1–M5, the three strands formed
a complex with the target DNA and UMB1. The fluorescent complex that contained
UMB1 had an arrangement of DNA strands similar to a DX tile,[7] which our lab
recently studied [35]. Importantly, the DX complex was tolerant to mutations since it
formed a long 36 base pair hybrid with the analyte (Figure 14). The OR gate was
designed to report the presence of any of the five different drug resistance-conferring
mutations across all three separate regions within the hypervariable 81-nt region of
the Mtb genome. The OR gate consisted of O and C strands. Each C strand was
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designed to recognize a specific mutant strain of Mtb that is known to cause Rif
resistance. Together, the five C and the three O strands formed five fluorescent
complexes with UMB2 and the five Mtb mutants, M1, M2, M3, M4, and M5 (Figures 12
and 13). Each fluorescent complex was formed only in the presence of the cognate
mutant analyte, but not WT. Therefore, overall performance of the complete set of all
O and C strands corresponded to OR logic, which produced a high fluorescent output
in the presence of any Mtb DNA containing one of the 5 selected SNP that confer Rifresistance, but low in the presence of WT. Pairs of O and C strands were optimized to
produce high signals only in the presence of cognate mutant sequence (Figures 12
and 13). Two different O strands, M1_M4-O and M2_M3-O were utilized as uniform
components for recognition of M1, M4 or M2, M3, respectively. Importantly, no signal
above the background was produced by the WT Rif-susceptible sequence (Figures 12
and 13). This was achieved by designing relatively short analyte-binding arms of all M
strands (7 nucleotides), which increased sensitivity for a mutation (Figure 12).
To create a functional assay, all DNA strands of both the YES and OR gates
were combined with UMB1 and UMB2 in one reaction mixture and the outputs of the
UMBs were measured at two different wavelengths (517 nm and 580 nm). Both the
OR and YES gates functioned according to the design: the YES gate produced high
output at 580 nm in the presence of both WT and the mutant sequences (Figure 15,
gray bars); the OR gate generated high signal at 517 nm in the presence of any of the
mutants but a low signal for the WT analyte (Figure 15, black bars). Therefore, the
combination of the YES and OR gates produced a high signal at 580 nm if any Mtb
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sequence is present, whereas a signal at 517 nm was observed only if a Rif resistant
mutant sequence was present. This signal pattern can be unambiguously used for
diagnostic purposes to answer the questions of the presence of an Mtb sequence and
its Rif susceptibility.
Discussion
PCR-based Mtb analysis is considered to be a new method to replace time
consuming culturing or error-prone sputum smear microscopy techniques [57,69]. The
Expert MTB/RIF assay can detect Mtb resistance in 2 hours with high selectivity [6365,72-74]. However, the approach is limited to interrogation of the 81- nt hypervariable
fragment of the Mtb genome. Detection of other mutations (for example, mutations
responsible for isoniazid resistance) would require introduction of additional MB
probes, while current rtPCR instruments register fluorescence from only a few (5 or 6)
channels. Importantly, if a sample is contaminated with the WT sequence, the assay
would produce a false negative for antibiotic resistance, as all five MB probes would
preferably bind the WT analyte, producing high fluorescent signal. Herein we propose
the combination of YES and OR DNA logic gates to achieve accurate detection of both
WT and Rif-resistant Mtb DNA sequences (Figure 16). The approach minimizes the
number of MB probes required for both the detection of Mtb and Rif resistance.
Therefore, a qPCR instrument with five detection channels can be replaced with a
more affordable two-channel thermal cycler. Alternatively, additional OR gates can be
designed to recognize other antibiotic-resistant Mtb strains if a multichannel qPCR
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instrument is available. Thus, the study presented herein can serve as the framework
for the development of a multiplex assay to determine Mtb presence as well as drug
resistance for all major first-line antibiotics. A multiplex assay of this nature would be a
valuable tool for health care providers. In either case, the presented approach is costefficient as the logic gates use unmodified DNA as adaptor strands, which are
inexpensive synthetic oligonucleotides. Earlier, our lab reported the design of DNA
logic gates that take advantage of MB probes as fluorescent reporters [27,28,32,33].
However, the constructs used expensive non-nucleotide modifications, which added to
the cost of custom-made oligonucleotides. The combination of adaptor strands O and
C reported herein is a new cost-efficient OR gate that demonstrates robust
performance. Impressively, the 13 oligonucleotides working together in solution clearly
demonstrated predictable digital response with no detectable crosstalk.
We anticipate that the use of additional strands for detection of other mutations,
including those responsible for resistance to isoniazid and other antibiotics, will not
compromise the performance of the assay. Indeed, the complex predesigned DNA
associates of hundreds of self-assembling DNA strands can be produced at a yield of
more than 90% [75,76]. Among numerous DNA logic gates reported to date, there are
few applications to solve challenging practical problems. We have demonstrated that
the combination of DNA logic gates can be used to perform a complex diagnostic task
efficiently, affordably, and reliably. This work is a step towards employing logic gates
as versatile tools for diagnosis of tuberculosis and other infectious diseases, which
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opens a new application of DNA nanotechnology and DNA computation in biology and
medicine.
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Figures and tables

Figure 11. Molecular Beacon (MB) probe-based strategies for analysis of Rifresistant Mtb.
A) Expert MTB/RIF five MB probe approach [63-65,74]. Absence of a signal from at least one MB
probe (for example, MB5) indicates the presence of Rif-resistant Mtb DNA.
B) Combination of YES and OR logic gates for the detection of Mtb and its resistance to Rif. The three
DNA strands (a, b, and c) form a complex with UMB1 and the analyte to report the presence of Mtb
DNA. A pair of O and C strands of the OR gate forms fluorescent complex with UMB2 and the
analyte only if a mutation responsible for Rif-resistance is present in the sequence. SNP = single
nucleotide polymorphism.
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Table 2. Sequences of oligonucleotides used in the DNA logic gate for Mtb DNA
analysis study.
Name

Sequence
5‘-/TMR/CCTGGAATCATCGAACAAAGCACAGCCAG
UMB 1
G/BHQ2/
UMB 2
5’-/FAM/GCGTTAACATACAATAGATCGC/BHQ1/
UMB 2’
5’-/FAM/GCGTTAACATACAATAGATCGC
a
5’-TGGCTGTGCTCAGCTGGCTG G
b
5’ TTCGACATGAATTGGCTTTG
c
5’- GTTGTTCTGGTCTGATTCCA
M1_M4-O 5‘-TATTGTGTCGGCGCTTGTGCGATC
M2_M3-O 5’-TATTGTGCGGGTTGTTCTGCGATC
M5-O
5‘-TATTGTGAATTGGCTCAGGCGATC
M1-C
5’-GCCCACAATGTTAACG
M2-C
5’-CCCAACAATGTTAACG
M3-C
5‘-CCCTGCAATGTTAACG
M4-C
5‘-GCCAACAATGTTAACG
M5-C
5‘-GGCCCATATGTTAACG
5’-GCACCAGCCAGCTGAGCCAATTCATGGACCAG
WT
AACAACCCGCTGTCGGGGTTGACCCACAAGCGCC
GACTGTCGGCGCTG
5’-GCACCAGCCAGCTGAGCCAATTCATGGACCAG
M1
AACAACCCGCTGTCGGGGTTGACCCACAAGCGCC
GACTGTGGGCGCTG
5’-GCACCAGCCAGCTGAGCCAATTCATGGACCAG
M2
AACAACCCGCTGTTGGGGTTGACCCACAAGCGCC
GACTGTCGGCGCTG
5’-GCACCAGCCAGCTGAGCCAATTCATGGACCAG
M3
AACAACCCGCTGCAGGGGTTGACCCACAAGCGCC
GACTGTCGGCGCTG
5’-GCACCAGCCAGCTGAGCCAATTCATGGACCAG
M4
AACAACCCGCTGTCGGGGTTGACCCACAAGCGCC
GACTGTTGGCGCTG
5’-GCACCAGCCAGCTGAGCCAATTCATGGGCCAG
M5
AACAACCCGCTGTCGGGGTTGACCCACAAGCGCC
GACTGTCGGCGCTG
* Red indicates polymorphism location.
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Figure 12. Design and performance of OR gate component for recognition of M1
analyte.
A) Fluorescent output and the complex formed by the OR gate component with M1 analyte. Strands
M1_M4-O and M1-C (200 nM) and UMB2 (25 nM) were incubated in the absence (red) or presence
of 500 nM WT (pink) or mutant M1 (green). Control sample (blue) contained only UMB2 (25 nM).
Spectrum of fluorescent output between 500 and 550nm with 485nm excitation was recorded after
15 minute incubation.
B) Graph depicts the mean of three independent measurements with one standard deviation for
fluorescent output at 517nm.
C) Native polyacrylamide gel electrophoresis (nPAGE) analysis of OR gate performance. Samples
were mixed as described in the Materials and Methods with UMB2 replaced by UMB2’ (no
quencher, see table 2 for the sequence). Samples contained the following oligonucleotides: Lane 1:
UMB2’; Lane 2: UMB2’, M1_M2-O and M1-C; Lane 3: UMB2’, M1_M4-O, M1-C and M1; Lane 4:
UMB2’, M1_M4-O, M1-C and WT; Lane 5: M1_M2-O; Lane 6: M1-C; Lane 7: M1. After 15 minute
incubation at room temperature, 20μL of nPAGE-loading buffer (50% glycerol, 50mM Tris-HCl pH
7.4, 50mM) was added to each sample. A total of 120μL of each sample was loaded into an
nPAGE (1.5 mm thick) and run for 30 min at 100 with 4 C water circulating through a Thermo-Owl
PD9S gel electrophoresis apparatus. The gel picture was taken without staining using a U:Genius
gel documentation instrument. The fluorescent complex corresponding to the tetrapartite associate
is indicated by the arrow.
D) Structure of fluorescent tetrapartite complex of M1_M4-O, M1-C, UMB2 and M1 analyte.
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Figure 13 Fluorescent output of OR gate components for M2-M5.
Corresponding strands O (200 nM), C (100 nM) and UMB2 (25 nM) were incubated in the absence
(red) or presence of WT (pink) or a mutant (green) (500 nM). Control sample (blue) contained only
UMB2 (25 nM). Fluorescent output at 517 nm with 485 nm excitation was recorded after 15 min
incubation. Graphs depict the mean of three independent measurements with one standard deviation.
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Figure 14. Design and performance of YES logic gate for recognition of Mtb WT
DNA sequences.
A) Fluorescent output from YES gate in the presence or absence of the DNA analytes. Strands a, b
(200 nM), c (100 nM) and UMB1 (25 nM) were incubated in the absence (red) or presence of
mutants M1-M5 or WT analytes (500 nM). Control sample (blue) contained only UMB1 (25 nM).
Fluorescent output at 580 nm with 550 nm excitation was recorded after a 15 minute incubation at
room temperature. Graph depicts the mean of three independent measurements with one standard
deviation.
B) Structure of fluorescent penta-partite complex containing: a, b, c, UMB1 and WT analyte.
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Figure 15. Combination of YES and OR gates for detection and mutation
analysis of Mtb DNA.
All OR gate, YES gate, UMB1, and UMB2 oligonucleotides were mixed together in the absence or
presence of each separate mutant or wild-type analytes. Fluorescence at 580nm for UMB1 (gray) or
517nm for UMB2 (black) was recorded after a 15 min incubation at room temperature. The graph
depicts the mean signal-to-background ratio (S/B) of three independent measurements. Error bars
represent the standard deviation. S/B was calculated as a ratio of fluorescence in the presence of
analyte over the fluorescence in the absence of analyte.
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Figure 16. Graphical representation of logic gate scheme for detection and
mutation analysis of Mtb DNA.
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CHAPTER 4: BINARY REAGENTS FOR INACTIVATION OF HIV-1
REVERSE TRANSCRIPTASE
Introduction
Design and development of probes that selectively recognize and subsequently
block a protein’s function are important for research and drug discovery. Classical
approaches have focused on optimization of inert small molecules that form noncovalent interactions with their target leading to only moderate affinity and reversible
inhibition of the target’s biological function. Interestingly, some of the most successful
commercial drugs interact with their targets through covalent interactions, so-called
“covalent inhibitors” [77-79]. Most of the covalent inhibitors currently approved for use
as drugs were discovered serendipitously. Recently, concerted efforts by academia
and industry have been made to rationally design and develop new covalent inhibitors
[77,78]. The main impetus behind the newly minted interest in covalent inhibitors is
due to the advantages they offer. These include lower dosing, uncoupling of
pharmacokinetics (PK) and pharmacodynamics (PD), and decreased likelihood of
resistance being formed against the inhibitor [77,80]. The limiting factor in wide-scale
development of covalent inhibitors is selectively controlling the formation of the
covalent bond with only a specific target. The predominant mechanism of action for
covalent inhibitors is inclusion of an electrophilic moiety capable of reacting with
nucleophilic amino acids on target proteins. Thus, the wide distribution of such amino
acids throughout the proteome causes difficulties achieved the necessary selectivity
for use as drug leads or chemical probes. Others have addressed this issue by using
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bioinformatics to select targets that contain a requisite nucleophilic amino acid that is
not present in similar proteins [77,81]. This ‘targeted covalent inhibitor” (TCI) approach
has found success in developing covalent inhibitors for kinases. The range of proteins
that can be targeted with the TCI approach is limited by the requisite of a unique
nucleophilic amino acid side chain. We hypothesize that a binary approach to
developing covalent inhibitors will allow a greater flexibility in designing probes to
selectively recognize and inhibiting a specific target.

Design of covalent inhibitors using the binary approach.
In this application of the binary approach, two analogs of ligands (Figure 2) that
bind adjacent sites of the target are conjugated to pre-reactive groups. These prereactive groups (Figure 2 half circles) are small molecules that fulfill three criteria.
First, it is necessary that pre-reactive groups be inert toward water and biological other
molecules. Second, pre-reactive groups should react with each other when in
proximity and proper orientation. Finally, the reaction between pre-reactive groups
should produce a new chemical group that is capable of reacting with, or modifying,
amino acid side changes, protein backbone, or nucleic acid backbone (recognition
event). Thus, upon binding of both ligands to the target, the pre-reactive groups will be
in proximity to react and form a reactive intermediate that subsequently reacts with
amino acids on the target, inhibiting its function. We recently reported a light-activated
two-component covalent inhibitor designed following the binary approach that inhibits
of T4 DNA polymerase. Importantly, we were able to directly compare a classical
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single covalent inhibitor approach to the binary approach and found significant
improvement in the selectivity of the binary inhibitor. The light-activated compounds
are useful for some research applications, however, it is our goal to develop a similar
inhibitor utilizing chemistry that does not require light. Such, light-free binary covalent
inhibitors would be useful as chemical probes for research and potentially as drug
leads. Herein, the binary approach is applied to the design of covalent inhibitors for
HIV-1 reverse transcriptase (RT), an important drug target and excellent model for
designing covalent inhibitors using the binary approach.

HIV-1 Reverse Transcriptase: a model target for the binary approach.
We chose HIV-1 reverse transcriptase (RT) as a model target because it is
especially amenable to targeting using a binary approach, is an important drug target,
and its activity is easily assayed in a variety of formats. RT is the enzyme responsible
for retrotranscription of the single stranded RNA genome of HIV. To accomplish this
critical task in the HIV life cycle, RT coordinates three separate enzymatic activities:
RNA-dependent DNA polymerase activity, ribonuclease H acitivty, and DNAdependent DNA polymerase activity [82,83]. RT is an asymmetric heterodimer with
66kDa and 51kDa subunits; the latter is a cleavage product of the former. RT has the
characteristic DNA polymerase structure, resembling a right hand with finger, palm,
and thumb substructures (Figure 17). The mechanism of RT polymerization is similar
to the mechanism described for other DNA polymerase. The polymerase active site is
located in the palm domain, and contains a triad of aspartic acid residues with
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coordinate magnesium ions required for synthesis. A primer and template DNA or
RNA bind to the finger domain, positioning the 3’-hydroxyl (3’OH) of the priming strand
at the active site. Near the active site and the critical aspartate residues lies the
nucleotide-binding site, where deoxynucleotide triphosphates (dNTPs) bind. Upon
binding of a dNTP that forms the correct Watson-Crick base pairing with the first free
base in the template strand, the confirmation of RT changes. The confirmation change
positions the 3’OH of the primer in the proper position to attack the alpha phosphate of
the incoming dNTP, forming a phosphodiester bond [82]. The structure and function of
RT make it an excellent target for applying the binary approach. Moreover, RT is an
excellent model to test new pre-reactive group chemistries.
The design of a covalent inhibitor for RT following the binary approach takes
advantage of the two natural ligand binding sites located near each other: the 3’ end of
the primer and the nucleotide binding site (Figure 17C yellow and green). Thus, the
two components of the inhibitor are analogs of the natural RT substrate: nucleotide
triphosphates. We chose dTTP since previous studies have shown that modification of
dTTP can be routinely accomplished and modified dTTP is still a suitable substrate for
many DNA polymerases, including RT. The RT will incorporate one of the dTTP
analogs and translocate down the template strand, moving the first component into the
first binding site, the 3’ end of the primer. Upon binding of the second component to
the nucleotide binding site, the two pre-reactive groups attached to the dTTP analogs
will be positioned close to each other, allowing them to react. This reaction should
generate a reactive chemical that subsequently reacts with available amino acid side
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chains on RT. Analysis of reported structures of RT show that two lysine residues
(Lys66 and Lys65) are nearby these binding sites and may be able to react under
proper conditions (Figure 17C Lys66 and Lys65).
HIV-1 RT Inhibitors
Current RT inhibitors are delineated into two classes: nucleoside reverse
transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors
(NNRTIs) [84,85]. NRTIs are delivered as nucleosides and phosphorylated to
respective nucleotide triphosphates by cellular kinases. NRTIs are known as “chain
terminators” due to their mechanism of action. NRTIs are competitive inhibitors that
once phosphorylated, compete with natural dNTPs for binding to the nucleotidebinding site on RT (Figure17C yellow). However, NRTIs lack a 3’OH, preventing any
further elongation, thus inhibiting its polymerase activity. NNRTIs are noncompetitive
inhibitors that bind at an allosteric site nearby the polymerase active site and are
thought to promote a conformational shift that decreases the polymerase activities of
RT. NNRTIs are highly prone to the development of resistance, but are still useful for
use in patients that are treatment naïve [86]. NRTIs are also prone to the the
development of resistance, but less so than NNRTIs. A major downside to NRTIs is
side effects associated with NRTI inhibition of the mitochondrial DNA polymerase
gamma [87,88]. However, NRTIs, the first RT inhibitors discovered, remain a critical
tool in treating HIV. Thus, despite the success of current HIV treatment regimens and
RT inhibitors, RT remains an important drug target that warrants further efforts to
develop new inhibitors. Particularly, RT is an excellent candidate to pursue
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development of covalent inhibitors, as this could directly address many of the current
limitations inhibitors. Thus, we chose RT as a model target to develop binary covalent
inhibitors.
Materials and Methods
Materials
All chemical were purchases from Sigma Aldrich or Fisher Scientific. The CA,
SB, and TF dTTP analogs were custom synthesized in the Kolpashchikov Lab by
Carlos Ledezma. All other dNTPs were from Promega or New England Biolabs. The
AZT triphosphate was purchased from ChemCyte.

Gel Analysis of HIV-1 RT Elongation Products
Samples (typically 15 μL) contained 50nM of HIV-1 RT (Worthington
Biochemical Corporation), 1 μM of FAM-primer(FAM-Primer: 5’/FAM/ GTC CCT GTT
CGG GCG CCA) and template (5’-C TGT GTG GTC GTT CTC TTG CTA TGG GCG
CCG AAC AGG GAC) in HIV RT RXN buffer (50 mM Tris pH8.3, 8 mM MgCl2, 40 mM
KCl). FAM-primer was purified by HPLC. For CA-TF experiments, 5μM of each CA,
TF, or dTTP analog was added, as indicated, followed by incubation at 37 °C. Aliquots
of each sample were removed at indicated time points (5, 10, 20 and 30 minutes) and
500μM of natural dNTPs were added. After incubation at 37 °C for an additional hour,
samples were quenched by addition of an equal volume of 2X dPAGE Loading Buffer
(LB) (95% Formamide, 20 mM EDTA (pH 8.0), 0.05% bromophenol blue). For SB-TF
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experiments the first analog was added to a final concentration of 10 μM followed by
30 minute incubation at 37 °C. The second analog was added to a final concentration
of 100 μM followed by 60 minute incubation at 37 °C. Next, 500 μM of all four natural
dNTPs (dATP, dCTP, dGTP, dTTP) were added to each sample, as indicated, and
incubated for 60 minutes at 37 °C. To stop the polymerase reaction, an equal volume
of 2X dPAGE LB was added to each sample. Control samples to evaluate elongation
by one base were quenched with dPAGE LB after the initial incubation period. For
both CA and SB experiments, all samples were heated for 5 minutes prior to loading
15 μL onto a 15

7 M urea denaturing PAGE gel that was typically run for 45 minutes

(or until sufficient separation as indicated by migration of bromophenol blue) at 400 V
with 55 °C water running through a Thermo Owl Electrophoresis apparatus. Gels were
rinsed in deionized water and visualized using a Syngene U:Genius Gel
documentation instrument which allowed detection of the fluorescently labeled FAMprimer with no additional staining.

Molecular Beacon Assay for HIV-1 RT Activity
Samples (typically 50 μL) contained 50 nM of HIV-1 RT (Worthington
Biochemical Corporation), 100 nM of MB probe, and 110 nM of 12-nt Primer
(sequences found in Figure18A) in HIV RT RXN buffer (50 mM Tris pH8.3, 8 mM
MgCl2, 40 mM KCl). CA, TF, dTTP, or AZT was added as indicated and samples were
transferred into wells of a ThermoNunc 96 well flat black polystyrene micro plate. After
a 5 minute incubation at 37 °C, 100 μM of dNTPs were added to each sample and
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fluorescent intensity was recorded at 517 nm (485 nm excitation) using an Infinite 200
Pro plate reader. After 30 minutes, an additional aliquot of MB and 12nt
primer/template mix were added to each sample and fluorescent intensity was
recorded for an additional 30 minutes. Validation of the assay is shown in Figure 18B.

Molecular Dynamics Simulation
Molecular Dynamics simulations were conducted using the Protein Databank
(PDB) structure 1RTD. 1RTD is a solved crystal structure of a ternary HIV-1 RT
structure containing RT, primer-template, and dTTP bound to the nucleotide-binding
site. Figure 19 shows the MD workflow used in this study. Each step is explained in
detail below. First, the dTTP ligand analogs were drawn in Chemaxon MarvinSketch,
cleaned in 3d, and exported to the PDB file format. Visual Molecular Dynamics (VMD)
(http://www.ks.uiuc.edu/Research/vmd/) [89] was used to align the thymidine base of
the ligand analogs with the base of the dTTP from the 1RTD structure. The newly
aligned dTTP analogs were saved, and the atom information (coordinates) of the base
and pre-reactive group was copied into the 1RTD PDB file followed by deletion of the
original dTTP base atoms and coordinates. The original ribose and triphosphate of the
dTTP in the 1RTD structure was kept in place as the best approximation of the
orientation that the triphosphate group of the dTTP analogs would assume. This
procedure was repeated for building structures that contained analogs translocated
one position into the primer as well as in the active site. Four total structures were built
(dTTP, SBdTTP, TFdTMP-SBdTTP, and SBdTMP-TFdTTP). After building the
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structures, they were placed in a water box using VMD. The CHARMM force field
[90,91] was used and ParamChem’s CGenFF program (cgenff.paramchem.org;
interface version 0.9.7.1 with force field 2b8) [90,92-94] generated the topology and
parameter files for the new pre-reactive groups. As with the structure, these parameter
and topology files were joined with the base and ribose from the general force field.
The VMD psfgen plugin was used to generate a PSF file for each system. NAMD
Molecular Dynamics Software (http://www.ks.uiuc.edu/Research/namd/) [95] was used
to perform MD simulations on the Stokes HPC at the University of Central Florida
Advanced Research Computing Center (UCF ARCC). NAMD of each strcutre was run
to minimize, equilibrate water, release constraints, fully equilibrate, and finally obtain
production MD data (Figure 19).
Results
Clavulanic acid (CA) and 2,3,5,6-Tetrafluoro-4-hydroxy-benzoic acid (TF)
pre-reactive group pair
Initially, the natural product clavulanic acid was selected as an ideal candidate
for use as a pre-reactive group. Clavulanic acid (CA) is an approved β-lactam
antibiotic that inhibits bacterial β-lactamases. CA was originally discovered as a
product of Streptomyces clavuligerus in 1976 [96], and has found widespread use in
combination with other traditional β-lactam antibiotics, commonly Amoxicillin, to treat
both Gram-positive and Gram-negative infections [97]. CA is a suitable candidate for
use as a pre-reactive group particular due to its two-step mechanism (Figure 20).
Experimental data support that upon initial binding of CA to the active site of its natural
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target β-lactamase, CA acylates a serine residue causing the lactam ring to open, and
yielding an imminium intermediate [96]. Tautomerization of the imminium intermediate
to an enamine intermediate enables acylation of an additional serine residue, resulting
in a cross-linked β-lactamase. To adapt CA for use as a pre-reactive group, we
proposed to use a nucleophilic pre-reactive group pair that can function similarly to the
initial β-lactamase serine residue, reacting with CA to reveal a reactive intermediate
that subsequently acylates an amino acid side chain in the active site of RT. An ideal
pre-reactive group pair for CA is 2,3,5,6-Tetrafluoro-4-hydroxy-benzoic acid (TF) due
to its pKa, predicted to be 6.4 for the key oxygen atom attached to the 4th position of
the benzylic ring. (Calculated using ChemAxon MarvinSketch). Thus, at cytosolic pH,
typically above 7 [98], approximately 80% of TF would be deprotonated and could be
acylated by CA if the two pre-reactive groups were in proximity. Importantly, these two
pre-reactive groups were also selected since they contained carboxylic acid groups
that could be used to attach these groups to dTTP through standard synthetic
procedures [99-102]. The structures of CA and TF analgos of dTTP are shown in
Figure 21.
The CA-TF binary reagent inhibited RT activity. CA and TF were incorporated
into a primer with a template that allowed incorporation of only one TF or CA in order
to simulate the use of chain terminating dideoxynucleotides (ddNTP) that would cause
chain termination. Alone, both analogs had minimal effect on RT activity. However, in
the presence of both analogs the RT activity was reduced significantly (Figure 22 and
23A). In an effort to confirm the covalent mechanism, we tested the effect of
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incubation time on RT inactivation. The effect of a covalent inhibitor can vary in
experiments with different incubation times due to the requisite time for the covalent
bond to form. A challenge which disallows the use of more traditional characterization
of an inhibitors effect on a target enzyme [77]. Surprisingly, incubation time had little
effect on the potency of the CA-TF binary reagent, under our experimental conditions
(Figure 22). In effort to further characterize the nature of the CA-TF binary reagent, we
used a molecular beacon RT activity assay that allows real time monitoring (Figure18).
These experiments confirmed the gel analysis, showing that CA-TF inhibited RT
(Figure 22). However, TF alone also significantly inhibited RT activity, likely due to the
much higher ratio of TF to primer/template in this assay compared to the gel analysis.
Interestingly, after 30 minutes an additional aliquot of the primer and MB probe were
added, and the sample containing both CA and TF failed to produce any increase in
fluorescent signal in the subsequent 30 minutes (Figure 23A). This result suggests
that the CA-TF binary reagent may indeed covalently inhibit RT. Next, to compare the
CA-TF binary reagent to traditional NRTIs we used commercially available
triphosphate of ziduvudine (AZT) in the same assay. In order to inhibit RT at the same
level as CA-TF during the first thirty minutes of the experiment, 10X the concentration
of AZT (100 μM) compared to total CA and TF was required (Figure 23B). Importantly,
after the second addition of primer and MB probe, even this sample showed an
increase in fluorescent intensity, indicated remaining RT activity. This was expected
since AZT does not covalently inhibit RT, and this result illustrates the potential utility
of a covalent mechanism of action.
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Despite these promising results using the CA-TF pair, additional pre-reactive
group pairs were explored due to difficulties with CA analog synthesis. Indeed, even
commercial efforts to produce CA for use as an antibiotic have been plagued by the
poor stability of this compound [97]. Our characterization failed to reliably determine
whether the compounds used in this study contained the complete clavulanic acid ring
or a decomposition product (data not shown). Fortunately, a related β-lactam
compound, sulbactam, showed improved stability [103,104], but still offers a similar
mechanism that is amenable to adaption for the development of a covalent inhibitor
using the binary approach.

Sulbactam(SB)-TF pre-reactive group pair
Sulbactam (SB) was originally designed and synthesized as an alternative for
clavulanic acid [105], and displayed lower reactivity but higher stability. Importantly,
similar to CA, SB is predicted to inhibit β-lactamases through a two-step mechanism
making SB an attractive option as a pre-reactive group (Figure 24) [106]. Additionally,
SB also contains a carboxylic acid that was used for attachment to dTTP (Figure 21).
The structure of the SB dTTP analog is shown in Figure 21. Since SB has a similar
mechanism as CA, TF is an ideal pre-reactive group partner.
The SB analog of dTTP alone had little effect on RT activity at low
concentrations (Figure 25). However, in the presence of both SB and TF, RT was
significantly inhibited. Interestingly, the potency was greater when TF was the first
analog added. Unfortunately, thorough characterization of SB analogs was plagued by
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similar setbacks as CA. However, the data presented herein provides an impetus for
more synthetic efforts as both SB and CA or their degradation products show
promising characteristics as pre-reactive groups in a covalent inhibitor designed by
following the binary approach. In order to explore the conformation of the SB and TF
pre-reactive groups in the RT active site and to aid in the design of future binary
inhibitors we performed molecular dynamics simulations.

Molecular dynamics (MD) of Sulbactam-TF binary reagent
MD simulations of various combinations of SB-TF binary reagent components
were performed in order to sample the conformations of the pre-reactive groups in the
active site of RT. Furthermore, MD simulations allowed us to sample the distances
between the pre-reactive groups and RT amino acids. We also sought any evidence to
explain the improved potency of TF-SB reagent when TF is incorporated into the
primer. The protein database structure 1RTD [83] was used as a template to build
structures for MD simulations. This structure contains the full RT heterodimer in a
ternary complex with a DNA primer-template and an incoming ddTTP bound in the
nucleotide-binding site (Figure 17). Thus, we built four different structures based on
this template. Each structure contained different dTTP or dTTP analogs in the 3’end of
the primer or in the nucleotide-binding site (Figure 17C yellow and green). As a
control, we used RT in complex with dTTP bound in the nucleotide-binding site (Figure
26A). In the second structure SBdTTP was bound to the nucleotide-binding site
(Figure 26B). The third structure contained SBdTMP incorporated into the primer and
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TFdTTP bound to the nucleotide-binding site (Figure 26C). The fourth structure had
TFdTMP incorporated into the primer and SBdTTP bound to the nucleotide-binding
site (Figure 26D). All four structures were prepped in the same way, and MD
production for each was collected (Table 3).
To assess the stability of each structure throughout the MD simulation, the root
mean square deviation (RMSD) was calculated. RMSD measures the difference in the
location of atoms throughout the trajectory. Thus, a low RMSD indicates a stable
structure, as the atoms are not deviating away from there original position. RMSD
values were calculated for the entire MD production trajectory in four different ways for
each structure. First, the entire system compared to the initial structure prior to MD
production. Second, the protein backbone compared to the initial structure prior to MD
production. Third, the DNA compared to initial structure prior to MD production.
Fourth, the protein backbone compared to the original 1RTD crystal structure. All four
structures were remarkably stable, with average RMSD values below 3 Å (Figure 27).
To ascertain whether any favorable conformations between the pre-reactive
groups and protein amino acids were formed during MD simulation, the distance
between various groups throughout the trajectories were measured. Interestingly, the
average distance between TF and SB in the SBdTMP-TFdTTP structure is greater
than 10Å (Figure 28). However, in the TFdTMP-SBdTTP structure, that same
combination which inhibited RT activity, the average distance is less than 10 Å.
Furthermore, in the TFdTMP-SBdTTP structure, the TF forms a stable interaction with
Lys66 due to the negative charge on the TF oxygen and positively charged lysine side
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chain. This structural conformation indicates a mechanism in which TF deprotonates
Lys66, which is located in a flexible loop (Figure26 green loop), allowing it to react with
SB bound in the nucleotide-binding site. Over all, the MD simulations support our
finding that TFdTMP-SBdTTP is more potent inhibitor of RT, due to the distances
between these critical residues and offers a potential mechanism worth expiring in
future studies.
Discussion
Chemical probes that covalently modify their target are extremely useful as
research tools and for drug design strategies [77,107]. Using the binary approach to
make covalent chemical probes offers selective control over the generation of the
reactive portion of the probe. Herein, the binary approach was applied to the design of
covalent inhibitors for RT, which we establish as a model for testing of future prereactive group pairs. The CA/SB-TF pre-reactive group pair was investigated and
shows promise as an ideal candidate for future use in binary reagents. This particular
reagent was explored using MD simulations to confirm possible confirmations that
would allow the pre-reactive groups to react with amino acids RT. This work also
creates a system to test other another important component of the binary approach
that can be optimized: the linker arm between the ligand and the pre-reactive group.
An allylamine linker arm was used in this study, and due to conjugation with the
thymidine ring, and limited rotatable bonds, only minor conformational changes were
observed during MD simulation. Future study of similar systems with more flexible
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linkers may reveal more favorable confirmations between the pre-reactive groups and
amino acid side chains on RT or other targets. In addition to new linker arms, efforts to
create robust synthetic procedures and thorough characterization of SB and CA
analogs will enable full characterization of the mechanism by which these reagents
inhibit RT. CA or SB might become a general pair of reagents that can easily be
conjugated to ligands for other targets to quickly generate a robust and selective
chemical probe.
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Figures and tables

Figure 17. HIV-1 reverse transcriptase is an excellent binary approach model
target.
A) Front surface rendering of HIV-1 RT [83]. Dark grey shows p51 subunit. The p66 subunit is
composed of the RNaseH domain (light grey), fingers (green), palm (yellow), and thumb (orange)
domains. A Primer (red) and template (blue) is bound to RT situating the 3’-end of the primer near
the polymerase active site located in the palm region.
B) Side view of RT.
C) Top view of RT; insert shows close up of polymerase active site. The nucleotide binding site and
primer 3’-end sites are adjacent, as required for use of the binary approach. Importantly, at least
one lysine is located nearby (8 angstroms) which may react with products of binary reagents.

56

Figure 18. Molecular beacon (MB) assay for real time monitoring of HIV RT
activity.
A) Sequence of MB probe (black) and primer (orange). The primer was designed so the 3’ end would
be adjacent to an adenine in the template to ensure that a dTTP analog would be encorporated.

B) Fluorescent intensity of MB probe in the absence or presence of RT and primer.
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Figure 19. Molecular Dynamics (MD) workflow.
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Figure 20. Mechanism for clavulanic acid inhibition of β-lactamase.
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Figure 21. CA, SB, and TF dTTP analog structures.
Clavulanic acid (CA), sulbactam (SB), and 2,3,5,6-tetrafluoro-4-hydroxy benzoic acid (TF) analogs of
dTTP were synthesized by acylating the amine group of the allyamine linker with N-hydroxysuccinimide
esters of each pre-reactive group, as previously described [99,101,102]. Green in dTTP structure
indicates allylamine linker arm.
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Figure 22. CA-TF Binary Reagent Inhibits RT.
A) Gel analysis of RT activity. Samples contents are indicated by color in part B.
B) Quantification of the gel bands from A.
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Figure 23. Comparison between binary reagent CA-TF and NRTI AZT.
A) CA-TF covalent inhibitor inactivates RT. During the first 30 minute incubation the CA-TF reagent
inhibits RT activity aproximatley 50%. However, after addition of another aliquot of MB and primer
at 30 minutes, the RT shows no activity in the CA-TF sample, indicating inactivation
B) AZT inhibits RT, yet even at concentration 10X higher than used for the CA-TF binary reagent, RT
retains residual activity during the entire 60 minute experiment.
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Figure 24. Mechanism of sulbactam inhibition of β-lactamase.
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Figure 25. SB-TF binary reagent inhibits RT.

64

Figure 26. Active sites of RT structures used in MD study.
A) dTTP: RT structure with dTTP bound to the nucleotide binding site.
B) SBdTTP. RT structure with dTTP bound to the nucleotide binding site.
C) SBdTMP_TFdTTP: RT structure with SBdTMP at the 3’end of the primer and TFdTTP bound to the
nucleotide binding site.

D) TFdTMP_SBdTTP RT structure with TFdTMP at the 3’end of the primer and SBdTTP bound to the
nucleotide binding site.
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Table 3. RT structures and production time from Molecular Dyanmics
Simulations
RT Structure
dTTP
SBdTTP
SBdTMP_TFdTTP
TFdTMP_SBdTTP

Production Time
8.8 ns
14.6 ns
12.5 ns
12.5 ns
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Figure 27. RMSD values for MD simulations.
The protein backbone or DNA (top right only) of all structures was aligned and RMSD values were
calculated using VMD RMSD trajectory tool by comparing each frame of MD simulation trajectory data
to either the initial structure prior to production or to the original crystal structure from the protein
database (1RTD). These RMSD indicate all structures were stable under the force field used in MD
simulation.
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Figure 28. Distance between pre-reactive groups and RT lysine residues.
In three of the MD structures, the distance between pre-reactive groups and RT lysine residues were
calculated through the entire trajectory. Measurements of SB were from the carbonyl carbon in the βlactam ring. TF was measured from the terminal oxygen. Lysine residues were measured from the
nitrogen in the lysine side chain.
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